Pellecchia 2004.

Methods	Study design: open‐label crossover RCT Study duration: not reported Study follow‐up period: 14 weeks including 1 week screening and 1 week washout period
Participants	Country: Italy Setting: outpatient HD centre Health status: stable adult HD patients receiving 3 times/wk dialysis with a diagnosis of RLS established according to IRLSSG criteria; patients agreed not to take any psychotropic drug (e.g. levodopa SR, dopamine agonists, antidepressants, and neuroleptics) at least 1 month before baseline evaluation Number: 11 Mean age ± SD: 56.2 ± 8.7 years Sex (M/F): 7/4 Exclusion criteria: patients with clinically significant orthostatic hypotension; unstable medical condition including serious cardiovascular, pulmonary, hepatic, or psychiatric disease; concurrent or past diagnosis of malignant melanoma
Interventions	Treatment group Ropinirole, 0.25 mg/d orally doubled every 5 days to a maximum dose of 2 mg/d for a period of 6 weeks 1 week washout period before switch to alternate therapy Control group Levodopa SR 25/100 mg once/d orally, doubled to a maximum of 50/200 mg once/d after 2 weeks, for a period of 6 weeks Co‐interventions None
Outcomes	Reduction in severity of RLS scores (IRLSSG: 0 to 24) at baseline, 6 weeks and at end of study Adverse events
Notes	Funding source not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer generated randomisation
Allocation concealment (selection bias)	Unclear risk	Open label
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label
Blinding of outcome assessment (detection bias) All outcomes	High risk	Open label
Incomplete outcome data (attrition bias) All outcomes	Low risk	Adverse events were clearly stated
Selective reporting (reporting bias)	Low risk	No evidence of selective reporting
Other bias	Unclear risk	Funding source not reported